Profound Medical Corp (PRN) - Total Liabilities

Latest as of June 2026: CA$12.56 Million CAD ≈ $9.08 Million USD

Based on the latest financial reports, Profound Medical Corp (PRN) has total liabilities worth CA$12.56 Million CAD (≈ $9.08 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Profound Medical Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.

Profound Medical Corp - Total Liabilities Trend (2012–2025)

This chart illustrates how Profound Medical Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PRN current and non-current assets.

Profound Medical Corp Competitors by Total Liabilities

The table below lists competitors of Profound Medical Corp ranked by their total liabilities.

Company Country Total Liabilities
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
USA $10.31 Million
Global Atomic Corp
TO:GLO
Canada CA$32.39 Million
RideNow Group, Inc.
NASDAQ:RDNW
USA $391.10 Million
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
India Rs5.10 Billion
Udaipur Cement Works Limited
NSE:UDAICEMENT
India Rs18.94 Billion
Ultra Chip
TWO:3141
Taiwan NT$1.24 Billion
Paramount Communications Limited
NSE:PARACABLES
India Rs3.51 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Profound Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PRN equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.46 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.25 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Profound Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Profound Medical Corp (2012–2025)

The table below shows the annual total liabilities of Profound Medical Corp from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 CA$74.30 Million
≈ $53.75 Million
+657.26%
2024-12-31 CA$9.81 Million
≈ $7.10 Million
-22.93%
2023-12-31 CA$12.73 Million
≈ $9.21 Million
+2.53%
2022-12-31 CA$12.42 Million
≈ $8.98 Million
+101.67%
2021-12-31 CA$6.16 Million
≈ $4.45 Million
-15.09%
2020-12-31 CA$7.25 Million
≈ $5.25 Million
-53.52%
2019-12-31 CA$15.60 Million
≈ $11.28 Million
+6.65%
2018-12-31 CA$14.63 Million
≈ $10.58 Million
+33.89%
2017-12-31 CA$10.93 Million
≈ $7.90 Million
+65.80%
2016-12-31 CA$6.59 Million
≈ $4.77 Million
+26.55%
2015-12-31 CA$5.21 Million
≈ $3.77 Million
+4968.41%
2014-12-31 CA$102.73K
≈ $74.31K
-99.68%
2013-12-31 CA$32.52 Million
≈ $23.53 Million
+76.57%
2012-12-31 CA$18.42 Million
≈ $13.32 Million
--

About Profound Medical Corp

TO:PRN Canada Medical Devices
Market Cap
$219.66 Million
CA$303.65 Million CAD
Market Cap Rank
#16294 Global
#495 in Canada
Share Price
CA$8.31
Change (1 day)
+0.97%
52-Week Range
CA$5.95 - CA$12.11
All Time High
CA$35.63
About

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedb… Read more